The conditional probabilities of survival in patients with anaplastic astrocytoma or glioblastoma multiforme

Lin, Chih-Lung; Lieu, Ann-Shung; Lee, K.S; Yang, Yi‐Hsin; Kuo, Tai-Hong; Hung, Mei-Hsiang; Loh, Joon‐Khim; Yen, Cheng-Fang; Chang, Chih-Hui; Howng, Shen-Long; Hwang, Shiuh-Lin

doi:10.1016/s0090-3019(03)00322-7

Cited by 45 publications

(27 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Likewise for AA, those surviving to 2 years had a conditional probability of living for another 3 years of 50.1% compared with the observed 5-year survival rate of 28.6%. 64 Even so, the outlook for patients with high-grade glioma remains bleak.…”

Section: Prognosismentioning

confidence: 99%

The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation

Garside¹,

Pitt²,

Anderson³

et al. 2007

Health Technol Assess

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA NIHR Health Technology Assessment ProgrammeT he Health Technology Assessment (HTA) Programme, now part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the costs, effectiveness and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care. The research findings from the HTA Programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service'. The HTA Programme is needs-led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects. First is the commissioned route. Suggestions for research are actively sought from people working in the NHS, the public and consumer groups and professional bodies such as r...

show abstract

Section: Prognosismentioning

confidence: 99%

The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation

Garside¹,

Pitt²,

Anderson³

et al. 2007

Health Technol Assess

View full text Add to dashboard Cite

show abstract

“…Estimates have since been extended to include primary nonmalignant brain tumours, thereby capturing all primary brain tumours 3,4 . Additionally, smaller-scale studies have also examined conditional survival probabilities for selected histologies, particularly glioblastoma multiforme (gbm) and astrocytic tumours [5][6][7] . Most recently, conditional survival probabilities were calculated for periods before and after 2005, to examine potential differences in brain tumour survival attributable to changes in treatment protocols 4,8 .…”

Section: Introductionmentioning

confidence: 99%

Conditional Survival after a Diagnosis of Malignant Brain Tumour in Canada: 2000–2008

Yuan¹,

Ross²,

Davis³

2017

Current Oncology

View full text Add to dashboard Cite

show abstract

“…2 These studies have explored CS in cancer of the CNS, [3][4][5] head and neck, 6 breast, [7][8][9][10][11] lung, 12-14 gallbladder, 15,16 stomach, 17 colorectum, [18][19][20] prostate, 21 ovaries, 22 and other sites. [23][24][25][26] These studies have found that, in general, CS improves over time most significantly in patients with advanced disease, in whom the survival curve drops off rapidly in the first 1 or 2 years after diagnosis and then stabilizes.…”

Section: Introductionmentioning

confidence: 99%

Conditional Survival and the Choice of Conditioning Set for Patients With Colon Cancer: An Analysis of NSABP Trials C-03 Through C-07

Zamboni

Yothers

Choi

et al. 2010

JCO

View full text Add to dashboard Cite

A B S T R A C T PurposeColon cancer overall survival (OS) is usually computed from the time of diagnosis. Survival gives the initial prognosis but does not reflect how prognosis changes with changing hazard rates over time. Conditional survival (probability of surviving y additional years given they have survived x years [CS or OS͉OS]) is an alternative measure that accounts for elapsed time since diagnosis, providing more relevant prognostic information. We extend the concept of CS to condition on the set of patients alive, recurrence-free, and second primary cancer-free (disease-free survival [OS͉DFS]). Patients and MethodsUsing data from National Surgical Adjuvant Breast and Bowel Project trials C-03 through C-07, 5-year OS͉DFS was calculated on patients who were disease free up to 5 years after diagnosis, stratified by age, stage, nodal status, and performance status (PS). ResultsFor stage II, OS͉DFS improved from 87% to 92% at 5 years. For stage III, OS͉DFS improved from 69% to 88%. Patients younger than 50 years showed OS͉DFS improvement from 79% to 95%; those older than 70 years showed no sustained increase in OS͉DFS. Node-negative patients with Ն 12 nodes resected showed little change (89% to 94%); those with more than four positive nodes showed an improvement (57% to 86%). Patients with a PS of 0 or 1 demonstrated a small improvement; those with a PS of 2 did not (64% to 58%). ConclusionPrognosis improves over time for almost all groups of patients with colon cancer, especially those with positive nodes. OS͉DFS is a more relevant measure of prognosis for those who have already survived disease free a period of time after diagnosis.

show abstract

The conditional probabilities of survival in patients with anaplastic astrocytoma or glioblastoma multiforme

Cited by 45 publications

References 6 publications

The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation

The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation

Conditional Survival after a Diagnosis of Malignant Brain Tumour in Canada: 2000–2008

Conditional Survival and the Choice of Conditioning Set for Patients With Colon Cancer: An Analysis of NSABP Trials C-03 Through C-07

Contact Info

Product

Resources

About